See more news releases in: Biotechnology
Innovative Targeting Solutions Initiates Research Collaboration
BURNABY, BC, Jan. 19, 2012 /PRNewswire/ - Innovative Targeting Solutions Inc. (ITS), the developer of the next generation fully human antibody technology (HuTARG), today announced the initiation of a research collaboration with Amgen Inc. (Thousand Oaks, CA). The agreement will allow Amgen to assess ITS's HuTARG technology for a broader potential collaboration in the future.
About Innovative Targeting Solutions Inc.
Founded in 2008, Innovative Targeting Solutions Inc. is a privately-held
company that has developed a next generation platform for the
generation of fully human antibody therapeutics using its proprietary
HuTARG technology. The HuTARG technology is a fully mammalian
technology that generates antibody diversity in vitro via RAG1/RAG2 mediated V(D)J recombination. For more information,
visit www.innovativetargeting.com
SOURCE Innovative Targeting Solutions Inc
Back to top
Custom Packages
Browse our custom packages or build your own to meet your unique communications needs.
PR Newswire Membership
Fill out a PR Newswire membership form or contact us at (888) 776-0942.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.
Featured Video
More in These Categories
Journalists and Bloggers
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
Free Investing Newsletter from Investor Uprising!
Learn to navigate the world's financial system and profit from leading companies.
Register for Investor Uprising, the people's investment site, for a free weekly newsletter, information, education and premium research including our latest IU Confidential Report - "All That Glitters: The Ultimate Gold Report".